Sectoral Asset Management Inc Bellus Health Inc. Transaction History

Sectoral Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$7.14 - $8.53 $705,432 - $842,763	98,800 Added 14.77%	767,829 $5.53 Million
Q4 2022 Feb 10, 2023	BUY	$8.22 - $10.76 $448,812 - $587,496	54,600 Added 8.89%	669,029 $5.5 Million
Q3 2022 Nov 10, 2022	BUY	$8.95 - $12.0 $1.01 Million - $1.36 Million	113,016 Added 22.54%	614,429 $6.49 Million
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $1.87 Million - $2.9 Million	-289,224 Reduced 36.58%	501,413 $4.63 Million
Q1 2022 May 10, 2022	BUY	$5.56 - $7.99 $381,810 - $548,681	68,671 Added 9.51%	790,637 $5.44 Million
Q4 2021 Feb 11, 2022	SELL	$5.26 - $8.3 $6.4 Million - $10.1 Million	-1,216,938 Reduced 62.76%	721,966 $5.81 Million
Q3 2021 Nov 15, 2021	BUY	$2.7 - $6.64 $1.85 Million - $4.55 Million	685,964 Added 54.75%	1,938,904 $11.9 Million
Q2 2021 Aug 16, 2021	SELL	$3.11 - $4.61 $68,420 - $101,420	-22,000 Reduced 1.73%	1,252,940 $3.9 Million
Q1 2021 May 14, 2021	SELL	$3.03 - $4.58 $1.28 Million - $1.93 Million	-422,000 Reduced 24.87%	1,274,940 $4.9 Million
Q4 2020 Feb 12, 2021	BUY	$2.27 - $3.3 $3.85 Million - $5.6 Million	1,696,940 New	1,696,940 $5.19 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Sectoral Asset Management Inc with notifications on news.